Merus (NASDAQ:MRUS) Shares Sold by Great Point Partners LLC

Great Point Partners LLC trimmed its position in shares of Merus (NASDAQ:MRUS) by 52.2% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 250,000 shares of the biotechnology company’s stock after selling 273,288 shares during the quarter. Merus makes up about 3.7% of Great Point Partners LLC’s portfolio, making the stock its 12th biggest holding. Great Point Partners LLC owned 0.37% of Merus worth $12,490,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. nVerses Capital LLC grew its position in Merus by 750.0% during the third quarter. nVerses Capital LLC now owns 1,700 shares of the biotechnology company’s stock valued at $85,000 after buying an additional 1,500 shares during the period. US Bancorp DE acquired a new stake in Merus in the third quarter valued at approximately $103,000. Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Merus by 24.7% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,467 shares of the biotechnology company’s stock worth $118,000 after buying an additional 489 shares during the period. Farallon Capital Management LLC purchased a new position in shares of Merus during the 2nd quarter valued at approximately $237,000. Finally, ProShare Advisors LLC acquired a new stake in Merus in the 2nd quarter valued at $242,000. 96.14% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

MRUS has been the topic of several recent analyst reports. The Goldman Sachs Group began coverage on shares of Merus in a report on Thursday, November 21st. They set a “buy” rating and a $73.00 price objective on the stock. HC Wainwright reissued a “buy” rating and set a $85.00 target price on shares of Merus in a report on Friday, November 1st. Guggenheim lifted their price target on Merus from $93.00 to $111.00 and gave the stock a “buy” rating in a research note on Tuesday, October 1st. Needham & Company LLC reissued a “buy” rating and issued a $85.00 price objective on shares of Merus in a research note on Wednesday, November 20th. Finally, UBS Group initiated coverage on shares of Merus in a research note on Thursday, October 24th. They set a “buy” rating and a $72.00 target price on the stock. One research analyst has rated the stock with a sell rating, twelve have issued a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, Merus currently has an average rating of “Buy” and an average price target of $85.45.

Merus Stock Up 1.1 %

Shares of MRUS stock opened at $45.87 on Wednesday. The firm’s 50-day moving average is $50.30 and its two-hundred day moving average is $51.85. Merus has a 12 month low of $22.26 and a 12 month high of $61.61.

Merus (NASDAQ:MRUS) last released its quarterly earnings data on Thursday, October 31st. The biotechnology company reported ($0.95) EPS for the quarter, missing analysts’ consensus estimates of ($0.90) by ($0.05). The business had revenue of $11.77 million during the quarter, compared to analyst estimates of $9.11 million. Merus had a negative net margin of 680.61% and a negative return on equity of 38.89%. As a group, equities analysts predict that Merus will post -3.89 EPS for the current fiscal year.

Merus Profile

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.